Search

News Subcutaneous zilucoplan –⁠ the end of necessary “trips” to the hospital for myasthenia gravis patients?

A study recently published in Lancet Neurology demonstrated the efficacy and safety of the subcutaneously administered complement component C5 inhibitor –⁠ zilucoplan –⁠ in the treatment of myasthenia gravis (MG). This drug has the potential to alleviate the severity of this disease and improve the quality of life of patients.

Source: Rare Diseases in Neurology 3. 4. 2024

News Is Six Months of Adjuvant Targeted Therapy Sufficient for Early Breast Cancer?

The inclusion of adjuvant targeted therapy with chemotherapy for early HER2-positive breast cancer significantly improved patient outcomes. Since 2006, based on data from registration studies, the gold standard for adjuvant therapy has been 12 months of trastuzumab administration. However, similar effects were observed in a smaller study with just 9 weeks of treatment. The presented clinical trial therefore investigated the non-inferiority of shorter treatment duration (6 months).

Source: Breast Carcinoma 23. 11. 2020

News New Technology Teaches Healthcare Professionals to Deliver Messages Patients Don't Want to Hear

Communication with patients and their relatives is often very challenging for doctors and nurses, especially when the patient or their family member is experiencing strong emotions. A new technology from the startup ComGuide is here to help healthcare professionals practice how to communicate most effectively. Jan Hrdlička, the co-author, explained how exactly this technology works, who it is suitable for, and how it was developed and continues to evolve.

Source: 3. 5. 2024

News Treatment Options for Advanced Parkinson's Disease Using Medical Devices (DAT)

A new treatment option for advanced Parkinson's disease (PD) using medical devices (DAT −⁠ device-aided therapy) is the intestinal infusion gel containing levodopa, entacapone, and carbidopa (LECIG). An article published in 2022 in the journal Therapeutic Advances in Neurological Disorders provides an overview of current DAT modalities in PD patients and presents LECIG as the latest extension of options in this area.

Source: Parkinson's Disease 14. 9. 2023

News Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors

Brigatinib is commonly used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) in the 2nd line after progression on a 1st-generation ALK inhibitor, crizotinib. American scientists in a phase II study focused on the efficacy of brigatinib in the treatment of patients with advanced NSCLC who had progressed on 2nd-generation ALK inhibitors.

Source: Non-Small Cell Lung Cancer 15. 2. 2021

News Combination of Candesartan with ACE Inhibitors in the Treatment of Hypertension and Heart Failure

Although the combination of ACE inhibitors and sartans is not recommended due to the higher incidence of complications, studies also indicate a positive effect of their concurrent administration. The potential use of dual blockade of the renin-angiotensin-aldosterone system (RAAS) is suggested in resistant hypertension, and results have also been described in the treatment of congestive heart failure. What do the recommendations say?

Source: Sartans in the Treatment of Hypertension 25. 5. 2020

Články časopisu Von Willebrand disease

Author of the article: P. Smejkal, M. Matýšková, M. Penka Source: Vnitřní lékařství | 3/2008 9. 3. 2008

News Benefit of Maintenance Therapy with Olaparib in Newly Diagnosed Advanced Ovarian Cancer

The SOLO-1 study evaluated whether the use of the PARP inhibitor olaparib in the maintenance treatment of patients with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer with BRCA 1/2 mutation leads to an improved prognosis for these patients.

Source: Ovarian and Breast Cancer 17. 3. 2020

News Effectiveness of Dietary Intervention in Irritable Bowel Syndrome –⁠ Results of a Network Meta-Analysis

A low FODMAP diet is often recommended to alleviate symptoms of irritable bowel syndrome (IBS). Although several randomized studies have been conducted to assess the effectiveness of this diet, a systematic evaluation has yet to be available, and individual studies have used various control interventions. Therefore, an international team of researchers decided to prepare a systematic literature review with a network analysis, recently published in the journal Gut.

Source: Irritable Bowel Syndrome 12. 10. 2022

News Do Asthma Bronchiale and COPD Represent a Risk Factor for Severe COVID-19 and Death?

It is well known that patients with bronchial asthma and chronic obstructive pulmonary disease (COPD) have a higher risk of severe course of common viral respiratory diseases. A study by Belgian authors involving several hundred individuals evaluated the risk of ICU admission and death due to COVID-19 in patients with asthma and COPD compared to patients without these conditions. The other goal was to determine whether these risks are influenced by inhalation corticosteroid therapy or not.

Source: Treatment of Asthma and COPD 8. 11. 2021

News Pitfalls of Levothyroxine Replacement Therapy

Hypothyroidism (reduced function of the thyroid gland) affects approximately 1-2% of the population. Its prevalence increases with age and it is more common in women. Synthetic thyroid hormone levothyroxine is used to treat hypothyroidism. It is a widely prescribed medication available in tablets of various strengths.

Source: Thyroid Disorders 8. 3. 2021

News CASE STUDY: Key Benefits of GLP-1RA in Diabetes Therapy in the Office of a General Practitioner

Modern therapy using glucagon-like peptide-1 receptor agonists (GLP-1RA) offers diabetics highly effective management of their primary condition as well as several other advantages: it reduces the risk of hypoglycemia, aids in weight loss, and has a positive impact on the heart and blood vessels, including increasing the chances of preventing and delaying the progression of micro and macrovascular complications. Early initiation of this treatment not only significantly improves diabetes control but also helps in preventing or delaying the development of atherosclerosis and cardiometabolic syndrome.

Source: Modern Treatment of Diabetes with GLP-1 Analogues 16. 5. 2024

News Dual therapy improves not only lung function but also quality of life in COPD patients

Chronic obstructive pulmonary disease (COPD) reduces the quality of life of patients and is one of the main causes of morbidity and mortality. According to international recommendations, the initial pharmacotherapy is recommended as monotherapy with LAMA (long-acting muscarinic antagonists) or LABA (long-acting beta-agonists), or their combination. A pooled analysis of 4 studies compared the early addition of LABA to LAMA in patients with moderate to severe COPD.

Source: COPD 15. 4. 2021

Články časopisu Some Controversies in Gynecology and Obstetrics

Author of the article: M. Velemínský ml., M. Velemínský st. Source: Česko-slovenská pediatrie | 10/2010 9. 10. 2010

News Obinutuzumab and Early Progression of Patients with Previously Untreated Follicular Lymphoma −⁠ Analysis of Data from the GALLIUM Study

The GALLIUM study demonstrated longer progression-free survival (PFS) in patients with previously untreated follicular lymphoma (FL) treated with obinutuzumab compared to rituximab. The aim of the exploratory data analysis was to evaluate the impact of obinutuzumab on the incidence of early disease progression and the relationship between early progression and overall survival (OS) of the patients.

Source: Non-Hodgkin Lymphomas and CLL 23. 4. 2020